St. Jude Medical Inc. (NYSE:STJ) got the FDA’s green light for the U.S. market’s first combined FFR/OCT blood vessel imaging system for diagnosis and treatment of coronary artery disease.
The Ilumien system combines St. Jude’s PressureWire Aeris wireless fractional flow reserve imaging technology, which allows physicians to visualize blood vessel characteristics, and its Extreme Resolution optical coherence tomography, which helps evaluate the severity of blood flow blockages in coronary arteries.